Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Conference call and webcast to be held at 4:30 p.m. ET
電話會議和網絡直播將於美國東部時間下午 4:30 舉行
NEW HAVEN, Conn., May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2024.
康涅狄格州紐黑文，2024 年 5 月 1 日/PRNewswire/-- Trevi Therapeutics, In 納斯達克股票代碼：TRVI）是一家處於臨床階段的生物製藥公司，該公司正在開發用於治療特發性肺纖維化（IPF）和難治性慢性咳嗽（RCC）的研究性療法Haduvio（口服納布啡ER），今天宣佈，高級管理層將於美國東部時間2024年5月7日星期二下午 4:30 主持電話會議和網絡直播，以提供公司更新並審查公司截至2024年3月31日的季度財務業績。
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international). A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
要通過電話參加電話直播，請撥打（888）317 6003（國內）或（412）317 6061（國際）。網絡直播可從公司網站的 “投資者與新聞” 欄目觀看 www.treviTherapeutic。活動結束後，該網絡直播的存檔重播也將在公司網站上公佈，爲期30天。
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi is also developing Haduvio for prurigo nodularis. Haduvio is a dual ĸ-opioid receptor agonist and μ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough.
關於 Trevi Therapeutics, Inc
Trevi Therapeutics, Inc. 是一家處於臨床階段的生物製藥公司，正在開發研究性療法Haduvio（口服納布啡ER），用於治療特發性肺纖維化（IPF）和難治性慢性咳嗽（RCC）中的慢性咳嗽。特雷維還在爲結節性瘙癢症開發Haduvio。Haduvio 是一種雙重阿片類藥物受體激動劑和 μ-阿片受體拮抗劑，可在大腦中樞和肺部外周起作用，有可能產生協同鎮咳作用，治療慢性咳嗽。
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal relief to patients. RCC affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe chronic cough. There are also no approved therapies for RCC in the US.
慢性咳嗽的影響是巨大的，通常會導致患者的社交、身體和心理生活質量下降。在IPF中，慢性咳嗽可能導致疾病惡化，並可能增加進展、死亡或需要進行肺移植的風險。IPF中沒有經批准的治療慢性咳嗽的療法，目前的治療方案對患者的緩解作用微乎其微。RCC影響多達10％的成年人群，而Haduvio向RCC的擴展有可能惠及患有中度至重度慢性咳嗽的患者。美國也沒有批准的RCC療法。
Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
美國緝毒局沒有計劃注射腸外納布啡。特雷維打算提議將Haduvio作爲口服納布啡ER的商品名。其安全性和有效性尚未經過任何監管機構的評估。
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
欲了解更多信息，請訪問 www.treviTherapeutic 然後關注 Trevi X （以前是 Twitter）和 領英。
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
投資者聯繫人
凱蒂·麥克馬納斯
Trevi Therapeutics, In
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
媒體聯繫人
羅莎莉亞·斯坎波利
914-815-1465
rscampoli@marketcompr.com
SOURCE Trevi Therapeutics, Inc.
來源 Trevi Therapeutics, Inc
譯文內容由第三人軟體翻譯。